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The primary region of factor IX that mediates binding
to bovine aortic endothelial cells resides in residues
3–11 of the N-terminal region known as the Gla domain.
Recently, it was proposed that the observed binding to
endothelial cells is actually a measure of the interaction
between factor IX and collagen IV (Cheung, W. F., van
den Born, J., Kuhn, K., Kjellen, L., Hudson, B. G., and
Stafford, D. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93,
11068–11073). To confirm that factor IX binds to collagen
IV and to examine the specificity of this interaction, we
used scanning force microscopy to examine factor IX
binding to collagen IV. We imaged collagen IV in the
presence and the absence of factor IX and observed spe-
cific interactions between factor IX and collagen IV. Our
results demonstrate that factor IX binds to collagen IV
at specific sites in the collagenous domain ;98 and ;50
nm from the C-terminal pepsin-cleaved end.
Factor IX (F.IX)1 is a 57-kDa zymogen of a serine protease
that participates in blood coagulation. Activated F.IX (factor
IXa), with its nonenzymatic cofactor, factor VIIIa, activates
factor X to factor Xa, which converts prothrombin to thrombin
in the penultimate step of the coagulation cascade. Mutations
in F.IX result in the bleeding disorder hemophilia B (1).
It has been observed that F.IX binds to bovine aortic endo-
thelial cells with high affinity (5 nM Kd) (2, 3) and that mutat-
ing residues 3–11 of F.IX eliminates this binding (4). Recently,
Cheung et al. (5) observed that in the presence of heparin, F.IX
has a similar binding affinity to collagen IV (C.IV) and sug-
gested that the endothelial cell binding site is C.IV.
C.IV is an extracellular matrix protein and a major compo-
nent of the basement membrane region of endothelial cells.
C.IV is a right-handed triple helix composed of two a1 chains
and one a2 chain, each of which is a left-handed helix (6). Each
of these chains encodes the repeating GXX sequence (where the
first X and second X can be any amino acid, but are frequently
proline and hydroxyproline, respectively) characteristic of col-
lagenous proteins (7–11). Two noncollagenous regions flank the
triple helical collagenous domain: a 7S domain on the N-termi-
nal end and an NC1 domain on the C-terminal end. The 7S
domain mediates tetramer formation between four C.IV mono-
mers joined at their N-terminal ends, whereas the globular
NC1 domain participates in dimer formation between the C-
terminal ends of two C.IV monomers (12, 13). The NC1 and 7S
domains mediate polymerization to form an extensive C.IV
network. Treatment of this network with pepsin produces C.IV
tetramers linked by their 7S domains (see Fig. 2). These tet-
ramers can be used in in vitro studies (12, 14).
Denaturation of C.IV with dithiothreitol or heat eliminates
binding (5), suggesting that F.IX binding to C.IV requires the
intact triple helix. It is not known, however, whether F.IX
binds to a single specific site or if there are numerous F.IX
recognition sites on the C.IV molecule. We used scanning force
microscopy (SFM) to localize F.IX binding on C.IV by directly
visualizing the interaction between F.IX and C.IV.
SFM (also called atomic force microscopy) is a powerful tool
for investigating the structure of protein-protein and protein-
nucleic acid complexes. SFM produces a topographic image of a
sample by scanning a surface with a nanometer scale tip at-
tached to a flexible cantilever. Consequently, it is possible to
obtain three-dimensional images of macromolecules that are
deposited on very smooth surfaces such as mica (reviewed in
Refs. 15 and 16). Because of the sensitivity of the instrument to
variations in the dimensions of macromolecules, SFM is an
excellent method for investigating the binding of F.IX to C.IV.
In this study, we imaged both F.IX and C.IV separately and
F.IX bound to C.IV tetramers. We observed two specific F.IX
binding sites and identified F.IX that was nonspecifically
bound to C.IV.
EXPERIMENTAL PROCEDURES
Proteins—F.IX was purchased from Enzyme Research Laboratories
(South Bend, IN). Human C.IV tetramers (from placenta) and heparin
were purchased from Sigma. Antibody A-5, which recognizes the F.IX
catalytic domain (17), was a generous gift from Dr. Kenneth Smith of
Emory University.
Solid Phase Binding Assay—To assure that the material used in this
study was functionally identical to that used by Cheung et al. (5), we
performed the binding assay as described (5) and obtained a Kd of ;60
nM, similar to that obtained in the earlier study.
Sample Preparation—Antibody A-5, which does not affect C.IV bind-
ing,2 was used to increase the apparent size of the F.IX molecule to
make F.IX more easily identifiable. To form F.IX and A-5 (F.IXzA-5)
complexes, F.IX (90 nM) and A-5 (18 nM) were incubated in TBS-CM (20
mM Tris, 150 mM NaCl, 2 mM CaCl2, and 1 mM MgCl2, pH 8.0) for 2 h at
4 °C. To form complexes between C.IV and F.IXzA-5, C.IV (50 mg/ml)
was incubated with F.IX (90 nM) and A-5 (90 nM) for 2 h at 4 °C in the
presence of 1 mg/ml heparin in TBS-CM (5). As a control, A-5 (18 nM)
was incubated with C.IV (50 mg/ml) and heparin (1 mg/ml) in the
absence of F.IX. Each sample was diluted 1:15 or 1:20 into TBS-CM,
and 10 ml of the diluted sample were deposited onto a freshly cleaved
mica surface. Consequently, the concentrations of F.IX and heparin at
the time of deposition were ;6 nM each, which is below the Kd values for
both F.IX and heparin binding to C.IV. These concentrations gave
optimal coverage and visibility of individual collagen molecules. After
allowing the samples to set for 5 s, the surfaces were thoroughly rinsed
five times with ;0.5 ml of doubly distilled water using a wash bottle.
This procedure removes salt but leaves proteins bound to the surface,
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i.e. F.IXzA-5 complexes bound to C.IV remained bound to the surface.
The surfaces were then dried with N2 and imaged in air.
SFM-TM Hardware—Images were obtained in tapping mode using a
Nanoscope IIIa from Digital Instruments (Santa Barbara, CA). Silicon
cantilevers (125 mm) with a resonance frequency between 300 and 350
kHz were used (Digital Instruments). The scan rate was 1.85 lines/s
with 512 lines/image. Images were flattened prior to analysis.
RESULTS
Visualizing Factor IX and A-5 and Collagen IV—F.IX, A-5,
and C.IV molecules were stable under repeated scans and had
consistent appearances in several different depositions. F.IX
molecules were globular, with a diameter of 16 6 2 nm (n 5 10,
where n is the number of molecules measured; Fig. 1). F.IXzA-5
complexes were globular with a diameter of 23 6 3 nm and a
height approximately twice that of F.IX (n 5 10; Fig. 1). C.IV
molecules were tetrameric (Fig. 2); however, some C.IV struc-
tures contained less than four monomers. The three “bumps”
indicated by small arrows in the 7S domain in Fig. 3A were
observed on tetrameric C.IV both in the presence and the
absence of F.IXzA-5.
C.IV deposited in the absence of F.IX and A-5 was essentially
free of features having F.IXzA-5 dimensions. In depositions
with both F.IXzA-5 complexes and C.IV, features on C.IV with
dimensions consistent with free F.IXzA-5 complexes were iden-
tified as bound complexes (Fig. 3). To assure that the complexes
were a result of F.IX association and not an interaction be-
tween A-5 and C.IV, we imaged both A-5 and C.IV alone (n 5
30) and F.IXzA-5 complexes and C.IV in the presence of 2 mM
EDTA (n 5 18), which inhibits F.IX binding to C.IV. In these
images, molecules associated with C.IV were randomly bound
to the collagenous domain (data not shown). Furthermore, in
the presence of EDTA, only a few F.IX molecules were associ-
ated with C.IV (data not shown).
Data Analysis—Only collagen molecules with clearly visible
N (7S domain) and C termini were analyzed. All distances were
measured using Digital Instruments software. Standard error
of measurement that was determined by measuring individual
collagen strands was 6 13 nm. The length distribution of the
collagenous domains (see legend to Fig. 2) of C.IV molecules
deposited in the absence of F.IX. A-5 was gaussian, with an
average of 318 nm and a standard deviation of 648. 132 com-
plexes were analyzed and two peaks (located at 98 6 13 and
50 6 13 nm) were observed (Fig. 4). These peaks were not due
to differences in monomer length, because the average lengths
of monomers with complexes bound at 98 and 50 nm were
316 6 24 and 315 6 28 nm, respectively. Both binding sites
were statistically significant when examined by the goodness of
fit of a binomial distribution (p , 10210 and 0.004 for the
binding sites located 98 and 50 nm from the C-terminal end,
respectively).
DISCUSSION
Our results support earlier conclusions (5) that F.IX recog-
nizes and binds with high affinity to C.IV and not to a contam-
inant protein in the C.IV preparation. The data in Fig. 4 reveal
that F.IX binding is localized to the C-terminal portion of the
C.IV monomer within two sharp peaks centered at ;98 and
;50 nm from the C-terminal end. The larger peak at 98 nm
likely represents a high affinity, specific F.IX binding site on
the collagenous domain, whereas the smaller peak may repre-
sent a secondary, specific F.IX binding site, having 3–4-fold
lower affinity for C.IV than the primary site.
Because the breadth of the entire F.IX distribution is too
large to be explained by errors in our measurements, we sug-
gest that the distribution represents both specifically bound
F.IX and F.IX that is nonspecifically bound to the C.IV mole-
cule. The stability of the specific complex is likely to be a result
FIG. 2. Top (A) and surface (B) views of C.IV tetramers and free
F.IXzA-5 complexes. The tetramers are from a deposition that con-
tains F.IX and A-5. C.IV deposited in the absence of F.IX and A-5
appears identical to these images. The scales are the same in views A
and B. The 7S domain and C termini of the molecules in the tetramer
are labeled in the inset to A. A bracket (L) indicates the collagenous
domain.
FIG. 1. Top and surface (inset) views of free F.IX and F.IXzA-5
complexes. The smaller (less intense) structures represent free F.IX,
whereas the taller (more intense) structures represent F.IXzA-5 com-
plexes. The observed increase in size of F.IXzA-5 complexes to free F.IX
is expected from the increase in molecular weight of the protein upon
antibody binding.
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of nonspecific interactions with the triple helix, as well as
interactions with specific amino acid residues. Therefore, it is
reasonable to expect F.IX to bind nonspecifically along the
length of C.IV. The large number of nonspecifically bound F.IX
molecules on the C.IV monomer strongly supports earlier sug-
gestions that F.IX interacts with the triple helix (5) and not
with a single peptide chain, because nonspecific binding would
not be expected if F.IX were interacting with a conformation-
ally distinct looped out region. This nonspecific binding is anal-
ogous to that observed for proteins that bind to DNA, which,
like collagen, is also a long regular helical molecule. Indeed, the
structurally regular “backbone” of the triple helical region may
provide a significant portion of the binding free energy, as is
observed for DNA binding proteins (18–20).
In general, the number of F.IX molecules bound specifically
and nonspecifically to C.IV is determined by the concentration
of nonspecific and specific binding sites and the relative bind-
ing affinities to these sites. According to a lattice binding model
(21), if F.IX interacts with 5–30 residues of the triple helix, the
number of potential binding sites for a single F.IX molecule is
approximately 1300. If we assume that F.IX has a single,
specific binding site, the concentration of nonspecific sites is
1300 times greater than the specific site. Consequently, if F.IX
has a 1300-fold higher affinity for its specific site versus its
nonspecific sites, we expect to observe ;50% of the F.IX mole-
cules to be bound specifically and 50% to be bound nonspecifi-
cally. Such a difference in specific and nonspecific binding
affinities is typical for DNA binding proteins (18–20). In our
study, ;55% of F.IX molecules is specifically bound to the C.IV
molecule, indicating that F.IX has ;1000-fold greater affinity
for its specific sites than its nonspecific sites.
Surprisingly, the nonspecifically bound complexes were ad-
jacent to the high affinity binding site (within 100 nm) and
were not spread across the entire length of the molecule. This
result is consistent with a mechanism of one-dimensional dif-
fusion in which microscopic associations and dissociations be-
tween F.IX and C.IV permit F.IX to “slide” or “hop” along the
C.IV molecule in transit to and from its specific site (22, 23). In
the absence of this mechanism, we would expect nonspecific
binding of F.IX to be governed by three-dimensional, diffusion-
controlled, random protein-protein associations, and therefore,
we would expect to observe F.IX binding across the entire
length of the C.IV molecule. Significantly, a similar distribu-
tion of binding has been observed for Cro binding to DNA,
which exhibits kinetics indicative of one-dimensional diffusion
(24).3 These results for F.IX binding to C.IV suggest that one-
dimensional diffusion may be important for protein-protein
interactions involving long regular structures, as well as for
DNA binding proteins.
From our measurements of the position of the specific F.IX
binding sites and from data on triple helix structure, we can
identify the regions of amino acids that mediate specific F.IX
binding to C.IV. C.IV differs from fibrillar collagens, because it
contains interruptions of noncollagenous sequences within its
collagenous repeats. Because these interruptions do not alter
triple helix propagation in the collagenous domain, it is un-
likely that they disrupt the triple-helical character of the col-
lagenous domain (6, 25–28). Accordingly, we assumed a linear
dependence of helical length for the 1304 amino acid residues
in the collagenous domain. This assumption allowed us to
localize F.IX binding to specific amino acid regions by meas-
uring the position of F.IX along the helix. From the 318 nm
measured length of the collagenous domain, we calculated a
distance of 2.44 Å per amino acid along each chain in the
collagenous domain, which is consistent with the published
value for a synthetic triple helical peptide (2.9 Å) (28). Using
this value, we concluded that the specific F.IX binding site
located 98 6 13 nm from the C-terminal end corresponds to
residues 985–1092 of the a1 chain and residues 1030–1137 of
the a2 chain (Fig. 5). Similarly, the secondary specific F.IX
binding site located 50 6 13 nm from the C-terminal end
3 D. A. Erie, unpublished observation.
FIG. 4. Distribution of distances of the F.IXzA-5 complexes
from the free (C-terminal) end of the C.IV monomers. 132 F.IXzA-
5-bound collagen molecules were analyzed. The data were divided into
20 nm bins for graphing; however, changes in the bin size (65 nm) did
not affect the significance of the peaks. Both of the peaks were statis-
tically significant (p , 0.0004).
FIG. 3. Top (A) and surface (B) views of F.IXzA-5 complexes
bound to C.IV. C termini, 7S domains, F.IXzA-5 complexes, and the
region measured for Fig. 4 (bracket, Lc) are indicated in the inset to A.
The scale in B is the same as in Fig. 1.
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corresponds to residues 1182–1288 of the a1 chain and residues
1227–1333 of the a2 chain.
A search of the amino acids surrounding the mapped F.IX
binding regions reveals several noncollagenous inserts within
the GXX collagenous repeats. Noncollagenous sequences at
residues 1056–1057 (GI) of the a1 chain and 1033 (K) and
1097–1100 (INLP) of the a2 chain are located within the iden-
tified primary specific binding region (FIX1 in Fig. 5). Addition-
ally, noncollagenous sequences at residues 939–947 (DKVD-
MGSMK) of the a1 chain and 980–990 (PVILPGMKDIK) of the
a2 chain flank the identified region. Residues 1182–1288 (a1
chain), which correspond to the secondary peak at ;50 nm
from the C-terminal end (FIX2 in Fig. 5), also contain several
noncollagenous sequences: residues 1231–1232 (TE) of the a1
chain, and residues 1235–1238 (NTLP), 1272–1277 (PPSNIS),
and 1305–1307 (ALP) of the a2 chain. Each of these noncollag-
enous regions most likely maintains the triple helical nature of
the collagenous domain (6, 25–28) and possibly provides con-
siderable specificity within the molecule. These sequences,
therefore, merit investigation in identifying the specific F.IX
binding sites on C.IV. Because several groups have successfully
constructed and characterized structurally intact triple helical
peptides (26–30), it may be possible to identify specific F.IX-
binding amino acid residues on C.IV using synthetic peptides
or alternatively, using site-directed mutagenesis.
Because heparin has been shown to increase the binding
affinity of F.IX to C.IV (5), it is interesting that the primary
specific F.IX binding site was located in the same region as a
previously identified heparin binding site (31) (FIX1 and HEP2
in Fig. 5). It is possible that heparin increases the affinity of
F.IX to the primary site on C.IV by binding to both F.IX and to
C.IV and stabilizing their interaction. It is unlikely, however,
that heparin is solely responsible for mediating this interaction
because F.IX binds to C.IV in the absence of heparin (5) and
because the heparin concentration used in this study is below
the measured Kd for the heparin-C.IV interaction. In addition,
we did not observe F.IX binding to the heparin binding site
proximal to the 7S domain (HEP1 in Fig. 5) (31), whereas we
did observe specific binding of F.IX ;50 nm from the C termi-
nus (FIX2 in Fig. 5) where there is no evidence for heparin
binding. Because two groups previously reported that heparin
fails to bind to pepsin-treated (tetrameric) C.IV (32, 33),
whereas Cheung et al. (5) showed that heparin increases the
affinity between F.IX and tetrameric C.IV, the exact role of
heparin in the interaction between F.IX and C.IV remains
unclear.
The collagens previously have been implicated in a variety of
physiological activities. Collagen types I, II, III, and IV induce
platelet adhesion (reviewed in Ref. 34). C.IV plays a role in cell
migration and cell binding during tumor metastasis (35). In-
deed, specific sites on C.IV have been identified that bind
heparin (31) and the integrins a1b1 (36), a2b1 (37), and a3b1
(38). Given the unique site on F.IX that interacts with C.IV and
the specificity of the recognition sites on C.IV, these results
strongly suggest that the F.IX-C.IV interaction is physiologi-
cally relevant. Whether this interaction is required for normal
hemostasis remains to be determined.
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